BioLife SolutionsBLFS -1.14%72 Debt-to-EBITDA is 5.12 as of Mar. 2026, which is 6300% above its 10-year median of 0.08. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.72 (Fairly Valued). The stock has 4 warning signs investors should review. Among 468 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 213675% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BioLife Solutions's Debt-to-EBITDA or its related term are showing as below:
BLFS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.76 Med: 0.08 Max: 10.42
Current: -1.31
During the past 13 years, the highest Debt-to-EBITDA Ratio of BioLife Solutions was 10.42. The lowest was -4.76. And the median was 0.08.
BLFS's Debt-to-EBITDA is ranked worse than 100% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs BLFS: -1.31
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BioLife Solutions Debt-to-EBITDA Related Terms
BioLife Solutions Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs STAA, ATRC, KMTS: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
BioLife Solutions (BLFS) has a Debt-to-EBITDA of 5.12 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioLife Solutions. This is 6300% above median its historical median of 0.08. According to the industry distribution chart, BioLife Solutions ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is BioLife Solutions' Debt-to-EBITDA too high?
BioLife Solutions' current Debt-to-EBITDA of 5.12 is 6300% above median its 10-year median of 0.08. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. BioLife Solutions' value of 5.12 is 229.3% above this industry median. Based on the distribution chart, BioLife Solutions ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Debt-to-EBITDA compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #999999 out of 468 companies for Debt-to-EBITDA. This places BioLife Solutions in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. BioLife Solutions' value of 5.12 is 229.3% above this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 1.56, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Debt-to-EBITDA of 5.12 is 229.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioLife Solutions. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Debt-to-EBITDA is 5.12, which is 6300% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.72, compared to a current price of $27.79 — trading 3.2% below its estimated fair value. The current Debt-to-EBITDA is 5.12, which is 6300% above median its 10-year median of 0.08 and 229.3% above the Medical Devices & Instruments industry median of 1.56. BioLife Solutions' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Debt-to-EBITDA is 5.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued.
The current stock price of $27.79 is trading 3.2% below its estimated GF Value™ of $28.72.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Debt-to-EBITDA: 5.12 (6300% above median its 10-year median of 0.08)
GF Value™: $28.72 vs. price of $27.79 (3.2% below fair value)
Industry Position: 229.3% above the Medical Devices & Instruments median (#999999 of 468)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
